Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema: - Trial NCT05847088
Access comprehensive clinical trial information for NCT05847088 through Pure Global AI's free database. This phase not specified trial is sponsored by Dar El Oyoun Hospital and is currently Completed. The study focuses on Diabetic Macular Edema. Target enrollment is 58 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Intravitreal Dexamethasone Implant for refractory Diabetic macular edema:
Observational
drug
Sponsor & Location
Dar El Oyoun Hospital
Timeline & Enrollment
N/A
Feb 15, 2023
Apr 04, 2023
Primary Outcome
Change in Central macular thickness (in microns) (CMT change ),Change in Best corrected visual acuity (BCVA change) )
Summary
We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing
 our results , evaluating both anatomical and functional outcomes of DEX therapy for
 refractory DME.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05847088
Non-Device Trial